{
  "id": 8052258,
  "title": "Novo partners with Orbis, deepening investment in oral peptide drugs",
  "url": "https://urgent.news/2026/09/17/novo-partners-with-orbis-deepening-investment-in-oral-peptide-drugs",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-17T15:55:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/novo-orbis-macrocyclic-peptides-oral-obesity-drugs/830645/"
  },
  "original_language": "en",
  "account": null,
  "summary": "The potentially $1.4 billion alliance will see the two companies collaborate on “macrocycles” that could yield oral treatments for cardiometabolic diseases.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}